Himalaya Therapeutics Announces Appointment of Nicholas Desjardins as Chief Financial Officer
News provided by
Share this article
Share this article
SAN DIEGO, April 19, 2021 /PRNewswire/ Himalaya Therapeutics ( Himalaya ), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics ( CAB ) technology platform, today announced the appointment of Nicholas Desjardins as chief financial officer and corporate development officer. In his roles, he will lead Himalaya s finance and accounting functions, as well as spearhead investor relations and corporate communications. He will work closely with the operations and strategy teams on strategic and licensing collaborations.